Evaluation Of The Effect Of SGLT-2 Inhibitors On Atrial Fibrillation Recurrence In Diabetic Patients
Completed
- Conditions
- Diabetes MellitusAtrial Fibrillation (AF)
- Registration Number
- NCT06951737
- Lead Sponsor
- Bursa Postgraduate Hospital
- Brief Summary
Consecutive DCCV was performed until to achieve 120 patients in SR (60 DM patients who used SGLT-2 inhibitors and 60 DM patients who did not use SGLT-2 inhibitors). Patients defined as SGLT-2 inhibitor user group and control group. The two groups were monitored for AF recurrence on the first day, then at one, three, and six months after CV.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- patients > 18 years and < 90 years,
- Patient diagnosed with DM
- Patient underwent electrical cardioversion due to AF and was restored to sinus rhythm
Exclusion Criteria
- patient who are not suitable for anticoagulant use,
- have thyroid dysfunction,
- glomerular filtration rate ≤ 25 ml/min/1.73 m²,
- patients whose sinus rhythm cannot be achieved with electrical cardioversion,
- malignancy patients,
- patients with acute or chronic inflammatory disease,
- patients with peripheral artery disease,
- patients with pacemakers,
- patients with advanced valve stenosis or insufficiency,
- patients who have had coronary bypass surgery,
- patients with percutaneous or surgical bioprosthesis or metallic valve surgery.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Atrial fibrillation recurrence six month
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Bursa Yüksek İhtisas Hastanesi
🇹🇷Bursa, Turkey
Bursa Yüksek İhtisas Hastanesi🇹🇷Bursa, Turkey